Stephanie L F Gustin1, Victoria Y Ding2, Manisha Desai2, Benjamin Leader3, Valerie L Baker4. 1. Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, Stanford University School of Medicine, 900 Welch Road, Suite 20, Palo Alto, CA, 94034, USA. sfisher@stanford.edu. 2. Quantitative Sciences Unit, Center for Biomedical Informatics Research, Stanford University School of Medicine, 1070 Arastradero Road, Palo Alto, CA, 94304, USA. 3. Clinical Research Division, ReproSource, Inc, 300 Tradecenter, Suite 6540, Woburn, MA, 01801, USA. 4. Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, Stanford University School of Medicine, 900 Welch Road, Suite 20, Palo Alto, CA, 94034, USA.
Abstract
PURPOSE: The objective of this analysis is to examine the relationship between Fragile X Mental Retardation 1 gene (FMR1) cytosine-guanine-guanine (CGG) repeat number and ovarian reserve, with a particular focus exclusively on the range of CGG repeat number below the premutation (PM) range (<55 CGG repeats). METHODS: Our study included female patients who underwent assessment of FMR1 CGG repeat number and serum anti-Mullerian hormone (AMH) in 2009-2014. To examine the association between FMR1 repeat number and serum AMH, we created three summary measures of CGG repeat number for the two alleles-"Sum," "Max," and "Gap" (absolute difference). Using multivariable regression models, controlling for age, we then analyzed the impact of these summary measures on AMH. RESULTS: A total of 566 patients were included in our study. Using multivariable regression models, we found that the relationship between CGG repeat number and AMH differed depending on age. Specifically, in younger women, AMH increased by 7-8 % (Sum p < 0.01, Max p = 0.04) for every 1 unit increase in CGG repeat number. In contrast, starting at age 40, there was a 3 to 5 % decline in AMH for every 1 unit increase in CGG repeat number (Sum p < 0.01, Max p = 0.04). CONCLUSIONS: This is the first study to report a statistically significant correlation of ovarian reserve and CGG repeat number in women with <55 CGG repeats. Although these women are generally considered to have a normal phenotype, our data suggest that increasing CGG repeat number within this normal range is associated with a more rapid decline in ovarian reserve.
PURPOSE: The objective of this analysis is to examine the relationship between Fragile X Mental Retardation 1 gene (FMR1) cytosine-guanine-guanine (CGG) repeat number and ovarian reserve, with a particular focus exclusively on the range of CGG repeat number below the premutation (PM) range (<55 CGG repeats). METHODS: Our study included female patients who underwent assessment of FMR1CGG repeat number and serum anti-Mullerian hormone (AMH) in 2009-2014. To examine the association between FMR1 repeat number and serum AMH, we created three summary measures of CGG repeat number for the two alleles-"Sum," "Max," and "Gap" (absolute difference). Using multivariable regression models, controlling for age, we then analyzed the impact of these summary measures on AMH. RESULTS: A total of 566 patients were included in our study. Using multivariable regression models, we found that the relationship between CGG repeat number and AMH differed depending on age. Specifically, in younger women, AMH increased by 7-8 % (Sum p < 0.01, Max p = 0.04) for every 1 unit increase in CGG repeat number. In contrast, starting at age 40, there was a 3 to 5 % decline in AMH for every 1 unit increase in CGG repeat number (Sum p < 0.01, Max p = 0.04). CONCLUSIONS: This is the first study to report a statistically significant correlation of ovarian reserve and CGG repeat number in women with <55 CGG repeats. Although these women are generally considered to have a normal phenotype, our data suggest that increasing CGG repeat number within this normal range is associated with a more rapid decline in ovarian reserve.
Authors: B Bodega; S Bione; L Dalprà; D Toniolo; F Ornaghi; W Vegetti; E Ginelli; Anna Marozzi Journal: Hum Reprod Date: 2005-12-16 Impact factor: 6.918
Authors: M Dólleman; M J Faddy; J van Disseldorp; Y T van der Schouw; C M Messow; B Leader; P H M Peeters; A McConnachie; S M Nelson; F J M Broekmans Journal: J Clin Endocrinol Metab Date: 2013-03-18 Impact factor: 5.958
Authors: A K Sullivan; M Marcus; M P Epstein; E G Allen; A E Anido; J J Paquin; M Yadav-Shah; S L Sherman Journal: Hum Reprod Date: 2004-12-17 Impact factor: 6.918
Authors: Michael D Wittenberger; Randi J Hagerman; Stephanie L Sherman; Allyn McConkie-Rosell; Corrine K Welt; Robert W Rebar; Emily C Corrigan; Joe Leigh Simpson; Lawrence M Nelson Journal: Fertil Steril Date: 2006-10-30 Impact factor: 7.329
Authors: Christian De Geyter; Nadira M'Rabet; Julie De Geyter; Stephan Zürcher; Rebecca Moffat; Nemya Bösch; Hong Zhang; Karl Heinimann Journal: Genet Med Date: 2013-10-10 Impact factor: 8.822
Authors: Thomas W Kelsey; Phoebe Wright; Scott M Nelson; Richard A Anderson; W Hamish B Wallace Journal: PLoS One Date: 2011-07-15 Impact factor: 3.240
Authors: Marsha Mailick; Jinkuk Hong; Jan Greenberg; Leann Smith Dawalt; Mei Wang Baker; Paul J Rathouz Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2017-04-13 Impact factor: 3.568
Authors: Bat-Sheva L Maslow; Stephanie Davis; Lawrence Engmann; John C Nulsen; Claudio A Benadiva Journal: J Assist Reprod Genet Date: 2016-05-17 Impact factor: 3.412
Authors: Alice J Shapiro; Sarah K Darmon; David H Barad; David F Albertini; Norbert Gleicher; Vitaly A Kushnir Journal: Reprod Biol Endocrinol Date: 2017-06-08 Impact factor: 5.211
Authors: Julia Rehnitz; Diego D Alcoba; Ilma S Brum; Jens E Dietrich; Berthe Youness; Katrin Hinderhofer; Birgitta Messmer; Alexander Freis; Thomas Strowitzki; Ariane Germeyer Journal: Reprod Biol Endocrinol Date: 2018-07-07 Impact factor: 5.211